How much funding does PROMISE Study Research Grant provide?

Funding amounts vary. Check the grant details for specifics.

When is the deadline for PROMISE Study Research Grant?

This grant has a rolling deadline or the deadline has not been announced.

PROMISE Study Research Grant

ADVANCING CANCER TREATMENT

Foundation Grants for Cancer Nonprofits Grants for Science Research

Apply Now

Funding Amount

Varies

Deadline

Rolling / Open

Grant Type

foundation

Overview

PROMISE Study Research Grant

Full Name: A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness (PROMISE)

Funder: Advancing Cancer Treatment (ACT)

Focus Areas:

Prostate cancer research

Germline genetic mutations (inherited genes) in prostate cancer

Understanding critical role of genetics in disease progression and treatment

Clinical trial matching and improved treatment options

Patient outcomes and survival

Funded Recipients/Collaborators:

UW Medicine: Collaborative research on germline genetic mutations; long-term study on prostate cancer causes, prevention strategies, diagnostics, and survival. UW has identified/assembled up to 80% of genes expressed in prostate cancer, developed one of largest serum and tissue banks, advanced studies of bone biology and skeletal metastases, assembled information on 300+ hereditary prostate cancer families.

Johns Hopkins Medicine: Prostate Cancer Program research crossing multiple specialties; studying detection, diagnosis, treatment approaches, genetic underpinnings, DNA methylation, inflammation's role in disease, and development of biomarkers to improve detection and guide personalized treatment.

Prostate Cancer Clinical Trials Consortium (PCCTC): Led by internationally recognized leaders; designs, implements, and completes early-phase clinical trials translating discoveries to improved standards of care. Manages efficient trial selection, reporting, site management, clinical operations, and data analysis for PROMISE study.

Research Goals:

Improve knowledge of germline genetic mutations in prostate cancer

Identify genetic risk factors

Develop biomarkers for detection, diagnosis, risk evaluation, and disease monitoring

Reduce overtreatment and quality-of-life impacts

Improve clinical trial matching and treatment options